CO6680653A2 - Fabricación del inhibidor inter-alfa(iaip) a partir de plasma - Google Patents

Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Info

Publication number
CO6680653A2
CO6680653A2 CO13035387A CO13035387A CO6680653A2 CO 6680653 A2 CO6680653 A2 CO 6680653A2 CO 13035387 A CO13035387 A CO 13035387A CO 13035387 A CO13035387 A CO 13035387A CO 6680653 A2 CO6680653 A2 CO 6680653A2
Authority
CO
Colombia
Prior art keywords
lalp
precipitate
fraction
plasma
manufacture
Prior art date
Application number
CO13035387A
Other languages
English (en)
Spanish (es)
Inventor
Shawn F Bairstow
Jennifer Hutsell
Sindhu Ramachandran
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6680653A2 publication Critical patent/CO6680653A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO13035387A 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma CO6680653A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23

Publications (1)

Publication Number Publication Date
CO6680653A2 true CO6680653A2 (es) 2013-05-31

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13035387A CO6680653A2 (es) 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Country Status (14)

Country Link
US (2) US8841248B2 (enExample)
EP (1) EP2596014B1 (enExample)
JP (1) JP5830096B2 (enExample)
KR (1) KR20130093607A (enExample)
CN (1) CN103119058A (enExample)
AU (1) AU2011280907B2 (enExample)
BR (1) BR112013001753A2 (enExample)
CA (1) CA2806645A1 (enExample)
CO (1) CO6680653A2 (enExample)
EA (1) EA201390156A1 (enExample)
ES (1) ES2717177T3 (enExample)
MX (1) MX2013000958A (enExample)
SG (1) SG187599A1 (enExample)
WO (1) WO2012012773A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
BR112013001753A2 (pt) 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之i-iv-1部分沉澱
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
EP3870147A4 (en) * 2018-10-24 2022-08-31 Prothera Biologics, Inc. INTER-ALPHA INHIBITOR PROTEINS AND METHODS OF USE THEREOF
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
KR20220029732A (ko) * 2019-07-04 2022-03-08 체에스엘 베링 게엠베하 C1-inh를 정제하는 방법
CA3173539A1 (en) * 2020-03-31 2021-10-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
EP4240757A2 (en) * 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
JP2025514479A (ja) * 2022-05-02 2025-05-02 武田薬品工業株式会社 血漿から限外濾過によりコーンプール濃縮物を調製する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
EP0764658B1 (de) * 1995-09-22 2002-01-02 ZLB Bioplasma AG Verfahren zur Gewinnung von Immunglobulinen aus Fraktionen, die bei der Fraktionierung von menschlichem Blutplasma entstehen
JP2004511492A (ja) 2000-10-13 2004-04-15 オクタファルマ アクチェン ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
EP2129686B1 (en) 2007-03-20 2016-07-13 CSL Behring GmbH Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
TR201808152T4 (tr) * 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
BR112013001753A2 (pt) 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.

Also Published As

Publication number Publication date
US8841248B2 (en) 2014-09-23
US20120053113A1 (en) 2012-03-01
JP5830096B2 (ja) 2015-12-09
JP2013535468A (ja) 2013-09-12
CA2806645A1 (en) 2012-01-26
KR20130093607A (ko) 2013-08-22
EA201390156A1 (ru) 2014-01-30
US20150045538A1 (en) 2015-02-12
MX2013000958A (es) 2013-11-20
WO2012012773A1 (en) 2012-01-26
ES2717177T3 (es) 2019-06-19
CN103119058A (zh) 2013-05-22
SG187599A1 (en) 2013-03-28
EP2596014B1 (en) 2018-11-28
BR112013001753A2 (pt) 2016-05-31
US9505814B2 (en) 2016-11-29
EP2596014A1 (en) 2013-05-29
AU2011280907A1 (en) 2013-02-07
AU2011280907B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
PH12014502524B1 (en) Carboxylic acid compounds
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
MX362512B (es) Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
EA201301181A1 (ru) Триазолопиридины
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX351467B (es) Nuevos derivados de fosfato de isoquinolinilcarbonilfenil indolizinilo o fosfato de isoquinolinilcarbonilfenil pirrolilo sustituidos, metódo para prepararlos y composiciones farmacéuticas que lo contienen.
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PE20141264A1 (es) Procedimiento de obtencion de una composicion que contiene factores de crecimiento a partir de un compuesto sanguineo, y composicion obtenible por dicho procedimiento
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
PH12014501342B1 (en) Cosmetic composition containing the slime of snails fed with red ginseng and method for manufacturing same
CL2017001588A1 (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
ECSP13012977A (es) Composiciones y métodos para separar, caracterizar y administrar selenoglicoproteínas solubles
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
EA201590564A1 (ru) Стабильные составы

Legal Events

Date Code Title Description
FC Application refused